Evome Medical Technologies Inc. (EVMT.V)
| Previous Close | 0.1750 |
| Open | 0.1700 |
| Bid | 0.1600 x N/A |
| Ask | 0.1700 x N/A |
| Day's Range | 0.1600 - 0.1700 |
| 52 Week Range | 0.1500 - 0.3250 |
| Volume | |
| Avg. Volume | 133,626 |
| Market Cap | 12.622M |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 21, 2024 - May 25, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 24, 2017 |
| 1y Target Est | N/A |
- GlobeNewswire
Evome Strengthens Major Creditor Relationship After the Sale of the Simbex Unit to Riddell, LOI Related to Simbex Acquisition Debt is Cancelled
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc (the “Company” or “Evome”) highlighted the strengthening credit relationship with Pathward, N.A. (“Pathward”), the Company’s senior lender. As the Company works to sell non-core business units to reduce acquisition debt in an effort to improve operational profitability, Pathward provides working capital to fuel revenue growth of the Company’s new Biodex products. Pathward has featured the strong and growing relationship
- GlobeNewswire
Evome Sells Simbex R&D Business Unit to Riddell for $4.83M in Cash; Improves Balance Sheet, Reduces Biodex Acquisition Debt
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) has reached an agreement with EB Sports Corp. (the “Buyer”), the parent company of Riddell Sports Group, an industry leader in football helmet technology and innovation, to sell Simbex LLC (“Simbex”), the Company’s R&D business unit, for approximately $4.83M in cash. The proceeds will be used to pay down Simbex debt and reduce Evome’s acquisition debt to the seller of its operati
- GlobeNewswire
Evome Medical Technologies Punctuates Turn Around Plan with Strong Fourth Quarter Resulting in Positive Annual Adjusted EBITDA for Fiscal Year 2023
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) announced today preliminary annual financial results for the year ending December 31, 2023. Because of a strong fourth quarter, the Company generated positive Adjusted EBITDA for 2023. Summary of Preliminary Annual Financial Results for 2023 Generated annual revenues of $62.6 millionGenerated annual gross margin of $22.5 millionAnnual gross margin as percentage of sales of 36%Generated annual
